Health-care companies rose after strong earnings from one fast-growing company.
Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the appearance of copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S.
Hims & Hers, the online pharmacy that recently struck a distribution deal with Novo Nordisk, saw shares rise.
If President Trump imposes drug tariffs that affect the cheap generic medicines Teva Pharmaceutical Industries makes, the company's chief executive says he'll have no choice but to raise their prices.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 07, 2025 17:32 ET (21:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.